Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2005 Oct;81(960):644–646. doi: 10.1136/pgmj.2004.032029

Psychosis in Parkinson's disease

B Thanvi 1, T Lo 1, D Harsh 1
PMCID: PMC1743370  PMID: 16210460

Abstract

Psychosis is common in Parkinson's disease (PD), particularly in its later stages. The symptoms range from comparatively minor illusions, vivid dreams, and occasional, non-disturbing visual hallucinations to frank psychosis. The pathogenesis of psychosis in PD is not fully known. Management of psychosis in PD requires a multidisciplinary approach. Some of the newer atypical antipsychotics are effective against psychosis with no significant worsening of PD. Psychosis in PD is associated with poor quality of life for patients and the carers.

Full Text

The Full Text of this article is available as a PDF (53.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes J., Boubert L., Harris J., Lee A., David A. S. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia. 2003;41(5):565–574. doi: 10.1016/s0028-3932(02)00182-3. [DOI] [PubMed] [Google Scholar]
  2. Barnes J., David A. S. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):727–733. doi: 10.1136/jnnp.70.6.727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bergman Joseph, Lerner Vladimir. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002 Mar-Apr;25(2):107–110. doi: 10.1097/00002826-200203000-00009. [DOI] [PubMed] [Google Scholar]
  4. Birkmayer W., Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37(2):175–182. doi: 10.1007/BF01663632. [DOI] [PubMed] [Google Scholar]
  5. Bodis-Wollner Ivan. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat Disord. 2003 Aug;9 (Suppl 2):S83–S89. doi: 10.1016/s1353-8020(03)00022-1. [DOI] [PubMed] [Google Scholar]
  6. Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002;18(5):258–264. doi: 10.1185/030079902125000813. [DOI] [PubMed] [Google Scholar]
  7. Factor S. A., Feustel P. J., Friedman J. H., Comella C. L., Goetz C. G., Kurlan R., Parsa M., Pfeiffer R., Parkinson Study Group Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10;60(11):1756–1761. doi: 10.1212/01.wnl.0000068010.82167.cf. [DOI] [PubMed] [Google Scholar]
  8. Fernandez Hubert H., Trieschmann Martha E., Friedman Joseph H. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004 Jan-Feb;27(1):4–5. doi: 10.1097/00002826-200401000-00003. [DOI] [PubMed] [Google Scholar]
  9. Fernandez Hubert H., Trieschmann Martha E., Okun Michael S. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord. 2005 Jan;20(1):104–105. doi: 10.1002/mds.20260. [DOI] [PubMed] [Google Scholar]
  10. Goetz C. G., Stebbins G. T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov;43(11):2227–2229. doi: 10.1212/wnl.43.11.2227. [DOI] [PubMed] [Google Scholar]
  11. Goetz C. G., Tanner C. M., Klawans H. L. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr;139(4):494–497. doi: 10.1176/ajp.139.4.494. [DOI] [PubMed] [Google Scholar]
  12. Graham J. M., Grünewald R. A., Sagar H. J. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):434–440. doi: 10.1136/jnnp.63.4.434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Graham J. M., Sussman J. D., Ford K. S., Sagar H. J. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):774–777. doi: 10.1136/jnnp.65.5.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Höflich G., Burghof K. W., Kasper S., Möller H. J. Elektrokrampftherapie bei Komorbidität einer therapieresistenten paranoid-halluzinatorischen Psychose mit Morbus Parkinson. Nervenarzt. 1994 Mar;65(3):202–205. [PubMed] [Google Scholar]
  15. Kulisevsky Jaime, Roldan Eliana. Hallucinations and sleep disturbances in Parkinson's disease. Neurology. 2004 Oct 26;63(8 Suppl 3):S28–S30. doi: 10.1212/wnl.63.8_suppl_3.s28. [DOI] [PubMed] [Google Scholar]
  16. Marsh L., Williams J. R., Rocco M., Grill S., Munro C., Dawson T. M. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004 Jul 27;63(2):293–300. doi: 10.1212/01.wnl.0000129843.15756.a3. [DOI] [PubMed] [Google Scholar]
  17. Merims D., Shabtai H., Korczyn A. D., Peretz C., Weizman N., Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm (Vienna) 2004 Oct;111(10-11):1447–1453. doi: 10.1007/s00702-004-0209-9. [DOI] [PubMed] [Google Scholar]
  18. Morgante Letterio, Epifanio Antonio, Spina Edoardo, Zappia Mario, Di Rosa Antonio E., Marconi Roberto, Basile Giorgio, Di Raimondo Giorgio, La Spina Paolo, Quattrone Aldo. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004 Jul-Aug;27(4):153–156. doi: 10.1097/01.wnf.0000136891.17006.ec. [DOI] [PubMed] [Google Scholar]
  19. Naimark D., Jackson E., Rockwell E., Jeste D. V. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc. 1996 Mar;44(3):296–299. doi: 10.1111/j.1532-5415.1996.tb00918.x. [DOI] [PubMed] [Google Scholar]
  20. Pollak P., Tison F., Rascol O., Destée A., Péré J. J., Senard J. M., Durif F., Bourdeix I. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004 May;75(5):689–695. doi: 10.1136/jnnp.2003.029868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sanchez-Ramos J. R., Ortoll R., Paulson G. W. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996 Dec;53(12):1265–1268. doi: 10.1001/archneur.1996.00550120077019. [DOI] [PubMed] [Google Scholar]
  22. Thanvi B. R., Munshi S. K., Vijaykumar N., Lo T. C. N. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J. 2003 Oct;79(936):561–565. doi: 10.1136/pmj.79.936.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Whitehouse P. J. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease. Adv Neurol. 1987;45:393–397. [PubMed] [Google Scholar]
  24. Wint Dylan P., Okun Michael S., Fernandez Hubert H. Psychosis in Parkinson's disease. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):127–136. doi: 10.1177/0891988704267457. [DOI] [PubMed] [Google Scholar]
  25. Zoldan J., Friedberg G., Livneh M., Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology. 1995 Jul;45(7):1305–1308. doi: 10.1212/wnl.45.7.1305. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES